advanced search
Aptar Pharma

Pulmonary & Nasal Delivery106

Issue No #106 Apr 2020  April 16th, 2020


Download PDF


Inside the magazine

IS NOW THE TIME TO SHAKE UP THE pMDI ENVIRONMENT?
RESPIRATORY
Chris Baron
Aptar Pharma
IS NOW THE TIME TO SHAKE UP THE pMDI ENVIRONMENT?
Chris Baron explores how the use of propellants in pressurised metered dose inhalers has evolved – and how alternative propellants could be a catalyst for greater patient adherence.
NEW DRUG-NEBULISER COMBINATION PRODUCTS: CONSIDERATIONS BEYOND PERFORMANCE
RESPIRATORY
Dr Nicolas Schwenck
PARI
NEW DRUG-NEBULISER COMBINATION PRODUCTS: CONSIDERATIONS BEYOND PERFORMANCE
Nicolas Schwenck and Michael Hahn summarise the critical success factors for bringing a new vibrating membrane nebuliser for a drug-device combination product to the market. They highlight opportunities and pitfalls – starting from the evaluation phase, through the development phase and finally during commercialisation.
OPTIMISING NASAL DRUG PRODUCTS FOR SYSTEMIC DELIVERY
NASAL
David Ward
Intertek Melbourn
OPTIMISING NASAL DRUG PRODUCTS FOR SYSTEMIC DELIVERY
David Ward discusses the benefits of systemic nasal delivery, describes a number of formulation strategies, and explains how to optimise absorption through properly informed formulation and device selection.
RETRONOSE: IMPROVING NASAL DELIVERY THROUGH A NEW AND IMPROVED DEVICE
NASAL
Dr Laurent Vecellio
Nemera
RETRONOSE: IMPROVING NASAL DELIVERY THROUGH A NEW AND IMPROVED DEVICE
Laurent Vecellio, Déborah Le Pennec, Guillaume Grevin and Alain Regard evaluate the performance of the RetroNose nasal drug delivery device.
OFF-THE-SHELF OR CUSTOM-MADE? CHOOSING A DRY POWDER INHALER
PULMONARY
Dr Philippe Rogueda
Merxin
OFF-THE-SHELF OR CUSTOM-MADE? CHOOSING A DRY POWDER INHALER
Philippe Rogueda discusses the manifold factors that need to be taken into account when choosing a dry powder inhaler – beyond just the target disease, formulation and patient population.
THE IMPORTANCE OF TRAINING AND ONBOARDING FOR INTRANASAL RESCUE THERAPIES
NASAL
Joe Masci
Noble
THE IMPORTANCE OF TRAINING AND ONBOARDING FOR INTRANASAL RESCUE THERAPIES
With a recent resurgence in nasal drug repurposing, Joe Masci looks at the importance of training and onboarding for intranasal rescue therapies.
RESPIRATORY DRUG DELIVERY: THEN, NOW AND SOON
EXPERT VIEW
Brennan Miles
RESPIRATORY DRUG DELIVERY: THEN, NOW AND SOON
Brennan Miles takes a look back at respiratory drug delivery over the last few decades to see what we can learn from the past – and looks ahead to what the future might look like, covering sustainability, device regulation, and formulation milestones.
PUBLIC INTEREST & INCENTIVES FOR INNOVATORS OF INHALED PRODUCTS
EXPERT VIEW
Dr Igor Gonda
PUBLIC INTEREST & INCENTIVES FOR INNOVATORS OF INHALED PRODUCTS
Igor Gonda, David Cipolla and Philippe Rogueda discuss the changes needed to increase the number of approved generic orally inhaled drug products (OIDPs) whilst providing additional incentives to innovators to meet the needs of the general public.
ADVANCING ASPRIHALE<sup>®</sup> TO PIVOTAL PK/PD STUDY
RESPIRATORY
Mark Stansfield
Otitopic
ADVANCING ASPRIHALE® TO PIVOTAL PK/PD STUDY
Mark Stansfield and Kambiz Yadidi discuss results of their pilot Phase I clinical study of dry-powder inhalation of aspirin.
HOSOKAWA EXTENDS BLENDER RANGE FOR DPI FORMULATIONS
RESPIRATORY
Bert Dekens
Hosokawa Micron BV
HOSOKAWA EXTENDS BLENDER RANGE FOR DPI FORMULATIONS
Bert Dekens announces the extension of the the company’s established Cyclomix modular blending technology range, to include small (R&D) scale, mid-range and large-scale systems.
THE OPTIONS FOR CREATING A MORE SUSTAINABLE INHALER
EXPERT VIEW
Phil Seeney
THE OPTIONS FOR CREATING A MORE SUSTAINABLE INHALER
With growing pressure to tackle climate change, Phil Seeney looks at the arguments in favour of creating more sustainable inhalers, and examines potential strategies to accomplish it.
DEVELOPING AN IN VITRO DISSOLUTION AND RELEASE SYSTEM FOR ORALLY INHALED DRUG PRODUCTS
RESPIRATORY
Dr Robert Price
Nanopharm
DEVELOPING AN IN VITRO DISSOLUTION AND RELEASE SYSTEM FOR ORALLY INHALED DRUG PRODUCTS
Robert Price critiques regulatory routes for the development of generic OINDPs, runs through recent announcements and developments of note from regulators, and describes how Nanopharma has pioneered the concept of structural Q3 equivalence.
ASTHMA & COPD: ENVIRONMENTAL SUSTAINABILITY & PATIENT-CENTRICITY
PHARMA VIEW
Dr Sara Panigone
Chiesi
ASTHMA & COPD: ENVIRONMENTAL SUSTAINABILITY & PATIENT-CENTRICITY
Sara Panigone, Federica Sandri and Gabriele Nicolini provide a considered and well-referenced analysis of carbon-minimal pMDIs for asthma and COPD, stressing the importance of balancing environmental sustainability with therapeutic efficacy to provide a sustainable and patient-centred solution.
INNOVATIVE DRUG-ELUTING ADHESIVES: APPLICATION IN CHRONIC RHINOSINUSITIS
EARLY INSIGHT
Dr Maria Pereira
Tissium
INNOVATIVE DRUG-ELUTING ADHESIVES: APPLICATION IN CHRONIC RHINOSINUSITIS
Maria Pereira, Elise DeVries and Camille Legros introduce novel applications in the treatment of chronic rhinosinusitis for the company’s programmable synthetic polymers and an associated delivery device.
Top